Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

University of Antwerp, Belgium.
British Journal of Cancer (Impact Factor: 4.82). 10/1996; 74(6):961-3. DOI: 10.1038/bjc.1996.465
Source: PubMed

ABSTRACT The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with < 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Intraperitoneal administration of paclitaxel-loaded expansile nanoparticles (Pax-eNPs) significantly improves survival in an in vivo model of malignant mesothelioma compared to conventional drug delivery with the clinically utilized Cremophor EL/ethanol (C/E) excipient. However, in vitro monolayer cell culture experiments do not replicate this superior efficacy, suggesting Pax-eNPs utilize unique drug delivery mechanisms. Using a mesothelioma spheroid model, we characterized the mechanisms of enhanced tumor cytotoxicity leveraged by Pax-eNPs.
    The Journal of thoracic and cardiovascular surgery 02/2015; DOI:10.1016/j.jtcvs.2015.02.020 · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chemotherapy is often the only treatment possible for locally advanced or metastatic mesothelioma. This paper recalls which drugs might have therapeutic benefits in this condition and reviews recent studies of chemotherapy or targeted therapy. If the patient cannot be enrolled in a therapeutic trial the first line therapy in the absence of contraindications is a combination of cisplatin and pemetrexed, the latter having received a licence for this indication in September 2004. Among the alternatives reviewed are taxanes, liposomal anthracyclines, topoisomerase inhibitors, cisplatin derivatives, vinca alkaloids, and antimetabolites. Although the first three have show little or no benefit the vinca alkaloids (vinorelbine, vinflunine) and particularly the antimetabolites (gemcitabine, raltitrexed, pemetrexed) are very promising. Recent studies have looked most frequently at combinations of an anti-metabolite and a platinum salt, with data available from nearly 200 patients treated with gemcitabine. These studies have had fairly homogeneous results showing a one year survival of about 50 %. Some preliminary data from studies of second line chemotherapy is also available. Finally studies of targeted therapies such as anti-EGFR, anti VEGF and anti PDGF are underway but have not as yet demonstrated major therapeutic benefit.
    Revue des Maladies Respiratoires 12/2005; 22(6):49-54. DOI:10.1016/S0761-8425(05)85772-9 · 0.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The EORTC Lung Cancer Group (LCG) maintains a multidisciplinary clinical trial portfolio. Over the years research has moved from investigators' ideas, to pharmacological company driven studies of new drugs, to the more recent biological marker driven studies. Non-small cell lung cancer (NSCLC) is the most common malignancy and has been the area of greatest activity. Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis which has been a surprising area of collaborative research in the LCG for many years. Small cell lung cancer (SCLC) is well named, as it has become ‘small’ in every way, and has changed from being the most hopeful of tumors to what has now become a trialist's despair. This review will provide a review of major clinical trials and the contribution of the LCG. Challenges and priorities in the way forward will be presented and discussed.
    EJC Supplements 03/2012; 10(1):99–104. DOI:10.1016/S1359-6349(12)70018-6 · 9.39 Impact Factor

Full-text (2 Sources)

Available from
May 19, 2014